Eisai and Meiji Seika Pharma have entered into a license agreement for the development and commercialization of safinamide for the treatment of Parkinson’s disease in Japan and Asia. Safinamide is currently under clinical development by Meiji in Japan. Eisai will obtain exclusive rights to safinamide to market in Japan and to develop and market in seven other Asian countries. Meiji will continue the clinical trials that it is currently conducting and submit a manufacturing and marketing autho...